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HIV and Hepatitis C–Coinfected Patients Have Lower Low-Density
Lipoprotein Cholesterol Despite Higher Proprotein Convertase
Subtilisin Kexin 9 (PCSK9): An Apparent “PCSK9–Lipid Paradox”
Payal Kohli, MD; Peter Ganz, MD; Yifei Ma, MS; Rebecca Scherzer, PhD; Sophia Hur, MPH; Bernard Weigel, BA; Carl Grunfeld, MD;
Steven Deeks, MD; Scott Wasserman, MD; Rob Scott, MD; Priscilla Y. Hsue, MD
Background-—Proprotein convertase subtilisin kexin 9 (PCSK9) inhibitors reduce low-density lipoprotein cholesterol (LDL-C) and
improve outcomes in the general population. HIV-infected individuals are at increased risk for cardiovascular events and have high
rates of dyslipidemia and hepatitis C virus (HCV) coinfection, making PCSK9 inhibition a potentially attractive therapy.
Methods and Results-—We studied 567 participants from a clinic-based cohort to compare PCSK9 levels in patients with HIV/HCV
coinfection (n=110) with those with HIV infection alone (n=385) and with uninfected controls (n=72). The mean age was 49 years,
and the median LDL-C level was 100 mg/dL (IQR 77–124 mg/dL); 21% were taking statins. The 3 groups had similar rates of
traditional risk factors. Total cholesterol, LDL-C, and high-density lipoprotein cholesterol levels were lower in coinfected patients
compared with controls (P<0.001). PCSK9 was 21% higher in HIV/HCV-coinfected patients versus controls (95% CI 9–34%,
P<0.001) and 11% higher in coinfected individuals versus those with HIV infection alone (95% CI 3–20%, P=0.008). After
adjustment for cardiovascular risk factors, HIV/HCV coinfection remained significantly associated with 20% higher PCSK9 levels
versus controls (95% CI 8–33%, P=0.001). Interleukin-6 levels increased in a stepwise fashion from controls (lowest) to HIV-
infected to HIV/HCV-coinfected individuals (highest) and correlated with PCSK9 (r=0.11, P=0.018).
Conclusions-—Despite having lower LDL-C, circulating PCSK9 levels were increased in patients coinfected with HIV and HCV in
parallel with elevations in the inflammatory, proatherogenic cytokine interleukin-6. Clinical trials should be conducted to determine
the efficacy of targeted PCSK9 inhibition in the setting of HIV/HCV coinfection. ( J Am Heart Assoc. 2016;5:e002683 doi:
10.1161/JAHA.115.002683)
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D yslipidemia is common in individuals infected with HIVand likely contributes to the higher rates of cardiovas-
cular complications that have been described in this patient
population, including acute myocardial infarction (MI) and
sudden cardiac death.1–4 Approximately 25% of all HIV-
infected patients are also infected with hepatitis C virus
(HCV).5 Several studies have reported that HIV/HCV coinfec-
tion is associated with an even higher risk of adverse
cardiovascular outcomes compared with individuals with HIV
infection alone.6,7 Further, both HIV and HCV infections can
alter lipid metabolism. HIV infection and certain antiretroviral
medications have been associated with higher low-density
lipoprotein cholesterol (LDL-C), lower high-density lipoprotein
cholesterol (HDL-C), and higher triglyceride (TG) levels.3,8,9 In
contrast, HCV infection alone has been associated with lower
total cholesterol (TC) and TG levels compared with uninfected
controls3 and HIV/HCV coinfection attenuates some of the
atherogenic lipid changes observed with HIV infection.10 One
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potential mechanism for these apparently lower atherogenic
lipids is the compromised synthetic capacity of the liver in the
setting of chronic viral infection that affects protein synthesis.
For example, our group has previously reported that HIV/HCV
coinfection is associated with a lower concentration of liver-
derived acute phase reactants, including C-reactive protein
(CRP), compared with HIV-infected individuals.11 Another
mechanism may relate to chronic systemic inflammation.12
Given the high prevalence of HIV/HCV coinfection, increased
rates of cardiovascular complications in this setting, and the
challenges of using statin therapy in the setting of chronic
hepatic disease, the discovery of novel and safe therapies for
treating dyslipidemia in such patients is an important
therapeutic goal.
Proprotein convertase subtilisin kexin 9 (PCSK9) modu-
lates cell-surface expression of LDL receptor (LDL-R), which
binds and removes LDL-C. Upregulation of PCSK9 leads to
increased degradation of LDL-R within the hepatocyte and,
therefore, higher circulating concentrations of LDL-C. Phar-
macologic inhibition of PCSK9 with the use of a monoclonal
antibody has resulted in substantial lowering of LDL-C by
50% to 80% without any serious adverse effects in multiple
short-term placebo-controlled trials among individuals without
HIV or HCV infection.13–19 It has also been shown to improve
cardiovascular outcomes in uninfected individuals in prelim-
inary studies.20,21 Because of their favorable safety profile,
lack of drug–drug interactions with antiretroviral or HCV
medications, and absence of hepatic toxicity, PCSK9 antibody
inhibitors may be an advantageous lipid-lowering therapy for
individuals coinfected with HIV and HCV.
We chose to study PCSK9 in the setting of HIV/HCV
coinfection for 2 reasons. First, PCSK9 is increased in
experimental models of inflammation.22 Second, PCSK9 is
synthesized in the liver and levels may be altered in the
setting of HCV infection because of hepatic injury or chronic
systemic inflammation, and, thus, PCSK9 levels may be
dysregulated when HCV infection is present along with HIV
infection. Therefore, the purpose of this study was to compare
PCSK9 levels among HIV/HCV-coinfected individuals, HIV-
monoinfected individuals, and uninfected controls. In addition,
as PCSK9 may be increased in systemic inflammatory states,
we sought to determine if PCSK9 levels in HIV/HCV-
coinfected individuals correlate with measures of systemic
inflammation (eg, interleukin [IL]-6) or with measures of
hepatic injury (eg, transaminase elevations).
Methods
Study Population
Four hundred ninety-five HIV-infected participants (385 with
HIV monoinfection, 110 with HIV/HCV coinfection) from the
SCOPE cohort (Studies of the Consequences of the Protease
Inhibitor Era) and 72 uninfected controls were included in
this study. The SCOPE cohort is a clinic-based cohort
consisting of well-characterized HIV-infected patients
enrolled at different sites within San Francisco. Our study
included SCOPE subjects who agreed to participate in a
carotid ultrasound substudy; these individuals were not
preselected for cardiovascular disease or symptoms in any
way. SCOPE recruitment included the following groups: (1)
untreated: no previous antiretroviral therapy [ART] or off ART
for 6 months; (2) treated/virologically suppressed: unde-
tectable HIV viral load for previous 6 months while on ART;
(3) treated/virologic noncontrolled: patients on ART, with HIV
RNA level ≥500 copies/mL; (4) elite controllers: untreated
individuals with ≥3 documented HIV RNA <2000 copies/mL
during a 12-month period; and (5) HIV-uninfected subjects
were recruited separately to provide age- and demographic-
matched controls. Control subjects were friends and
acquaintances of HIV-infected individuals and have been well
characterized by our research group previously.23 All controls
were tested and documented to be HIV negative before study
enrollment. The protocol, including the blood collection, was
approved by the University of California, San Francisco
Committee on Human Research, and written consent was
obtained from all patients.
PCSK9, Lipid, and Biomarker Measurement
Fasting blood samples were obtained at enrollment, and
plasma was isolated within 60 minutes of sample acquisition.
Plasma samples were stored in plastic cryovials at a
centralized storage facility (San Francisco, CA) where they
were maintained at 80°C during storage and shipping.
Soluble PCSK9 was measured by using a high-affinity ELISA
(Amgen Inc) at an Amgen testing facility in Richmond, VA, by
personnel blinded to clinical characteristics of the patients.
The CV of the assay was ≤4%, with a range of quantification of
15 to 1200 ng/mL and a Kd of 16 pmol/L.
Fasting blood samples were also used to measure TC, LDL-
C, HDL-C, and TG levels. The San Francisco General Hospital
clinical laboratory was used to measure CD4+ T-cell count and
HIV RNA levels, and the nadir CD4+ T cell count was the
lowest laboratory-confirmed value before study enrollment. IL-
6 and high-sensitivity CRP (hsCRP) levels were measured
using by standard ELISAs.
Participants were followed until August 2015 or until time
of death as determined by using the National Death Index.
Statistical Analysis
All analyses were conducted with use of SAS version 9.4 (SAS
Institute Inc). The baseline characteristics of control, HIV-
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monoinfected, and HIV/HCV-coinfected subjects were com-
pared by using v2 tests for categorical predictors, ANOVA for
normally distributed age, and Wilcoxon rank sum test for all
other continuous predictors, which were not normally dis-
tributed even after log transformation. PCSK9 was found to be
right-skewed and showed evidence of heteroskedasticity,
even after log transformation. Use of log linear ordinary least
squares in such circumstances has been shown to lead to
biased estimates.24,25 We therefore used generalized linear
regression with a log link function and Poisson pseudo-
maximum likelihood estimator with a robust variance estima-
tor24–26 to determine associations of HIV- and HCV-infection
status with levels of continuous PCSK9. Based on this
analysis, percentage differences and the corresponding 95%
CIs were estimated. Models were adjusted for demographic
variables (age, sex, race), statin use, and smoking status as
these variables are known to be associated with PCSK9
levels.27–29 LDL-C was not adjusted for as it is directly related
to PCSK9 levels via regulation of the LDL-R. Sensitivity
analyses were conducted to determine the effect of HIV and
HCV status among individuals with treated and virologically
suppressed HIV disease only. We also directly compared
PCSK9 levels between uninfected controls and HIV-infected
subjects, uninfected controls and HIV/HCV-coinfected
subjects, and HIV-monoinfected with HIV/HCV-coinfected
individuals.
Results
Baseline Characteristics
The median age of the overall cohort was 50 years (IQR 43–
55 years), with 87% men, 35% subjects who were smokers,
and 26% subjects with hypertension. The median LDL-C level
was 100 mg/dL (IQR 77–124), and 21% were taking statins.
HIV-monoinfected, HIV/HCV-coinfected, and uninfected con-
trols were generally similar in age, body mass index, blood
pressure, and rates of diabetes, with some exceptions such as
sex and race. Coinfected persons were more likely to be
female, black, and smokers compared with HIV-infected
individuals and controls. HIV/HCV-coinfected persons had
lower rates of statin use relative to uninfected and HIV-
monoinfected persons (Table 1).
HIV-Related Features
HIV-monoinfected and HIV/HCV-coinfected individuals had
similar HIV disease characteristics (Table 2). Overall, the
median duration of HIV infection was 15 years (IQR 8–21)
with a median CD4+ count of 527 cells/mm3 (IQR 346–732)
and a median HIV RNA level of 75 copies/mL. More than two-
thirds of the individuals (67.5%) were currently taking ART,
and 56% of these treated individuals had an undetectable HIV
RNA level of <75 copies/mL.
Lipid Profiles
As shown in Figure 1, there were notable differences in the
lipid profiles of the 3 patient groups. Specifically, HIV/HCV-
coinfected patients had significantly lower levels of TC, LDL-C,
and HDL-C compared with HIV-monoinfected patients and
uninfected controls. TG levels were highest in HIV-infected
individuals, with a median concentration of 310 mg/dL (IQR
213–496), and lowest in uninfected controls, with a median
concentration of 239 mg/dL (IQR 186–328).
PCSK9 Levels
Compared with controls, HIV/HCV-coinfected patients had
21% higher PCSK9 (95% CI 9–34%, P<0.001), while HIV-
monoinfected individuals had 9% higher PCSK9 (95% CI 1%
to +19%, P=0.07) (Figure 2). Compared with HIV-monoin-
fected subjects, HIV/HCV-coinfected individuals had 11%
higher PCSK9 (95% CI 3–20%, P=0.008). In a fully adjusted
model that accounted for age, sex, race, smoking status, and
statin use, HIV/HCV coinfection remained associated with
21% higher PCSK9 (95% CI 9–35%, P<0.001) compared
with controls and 14% higher in coinfected patients compared
with individuals with HIV monoinfection (95% CI 5–24%,
P=0.001). Because of colinearity with HCV, we did not adjust
for intravenous drug use.
These findings persisted when the analysis was restricted
to treated and suppressed HIV-infected individuals only;
namely, HIV-monoinfected patients had 10% (95% CI 0.4–
21%, P=0.04) and coinfected patients had 20% (95% CI 5.8–
36.7%, P=0.005) higher PCSK9 levels compared with controls
in a univariate model. In a fully adjusted model that adjusted
for age, sex, race, smoking status, and statin use, HIV/HCV
coinfection remained independently associated with 19%
higher PCSK9 levels relative to controls (95% CI 5–36%,
P=0.006). However, in the restricted analysis of treated and
suppressed HIV patients, the association between higher
PCSK9 with HIV monoinfection alone was no longer signif-
icant (percent different 6.7%, 95% CI 2.6% to 17.0%,
P=0.16).
Association Between Inflammatory Markers (IL-6,
hsCRP) and LDL-C and PCSK9
Median concentrations of the proinflammatory cytokine IL-6
increased in a stepwise fashion, from 1.5 to 2.2 to 2.9 pg/
mL, from uninfected controls to HIV-monoinfected individuals
to HIV/HCV-coinfected individuals, respectively. This increase
paralleled the stepwise increase in PCSK9 levels (Figure 3).
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Among all individuals, IL-6 had a modest positive correlation
with PCSK9 (r=0.11, P=0.018) (Figure S1A) and negative
correlation with LDL-C (r=0.12, P=0.01) (Figure S1B); IL-6
remained modestly correlated with PCSK9 levels when
restricted to HIV-monoinfected patients (r=0.14, P=0.009).
In a model that was adjusted for demographics, statin use,
smoking, and IL-6, PCSK9 levels remained significantly higher
among HIV/HCV-coinfected individuals compared with con-
trols (percent different 21%, 95% CI 8.4–35.6%, P=0.001) and
compared with HIV-infected individuals (percent different
14%, 95% CI 4.5–25.0%, P=0.003).
In contrast to IL-6, there was no significant difference in
baseline levels of hs-CRP among controls, HIV-infected
individuals, and HIV/HCV-coinfected individuals (median
1.3 mg/L [IQR 0.65–3.1] versus 1.5 mg/L [IQR 0.8–3.5]
versus 1.3 mg/L [IQR 0.6–3.7], respectively, P=0.17); corre-
lations of hs-CRP with PCSK9 were weak overall in the cohort
(r=0.03, P=0.42) and did not reach statistical significance in
any of the 3 groups.
There was no correlation between LDL-C and PCSK9 levels
in any of the 3 groups or overall (data not shown).
Hepatic Injury Markers: Alanine Transaminase
and Aspartate Transaminase
In all patients, the correlation coefficient r between alanine
transaminase (ALT) and PCSK9 was 0.03 (P=0.49) and that
between aspartate transaminase (AST) and PCSK9 was 0.09
(P=0.05). When restricted to only those patients with HIV/
HCV coinfection, these values attenuated to r=0.02
(P=0.82) and r=0.03 (P=0.74) for ALT and AST, respec-
tively. Both ALT and AST, when added to the fully adjusted
models separately, reduced the association with PCSK9
from 21% to 16% for HIV/HCV-coinfected patients com-
pared with the controls and from 14% to 13% for HIV/HCV-
coinfected patients compared with the HIV-monoinfected.
Neither ALT nor AST reached statistical significance, while
the association between HIV/HCV coinfection and PCSK9
Table 1. Baseline Characteristics of Uninfected Controls, HIV-Monoinfected Patients, and HIV/HCV-Coinfected Patients From the
SCOPE Cohort
Uninfected (n=72) HIV Infected (n=385) HIV/HCV Coinfected (n=110) P Value
Age, y 52 (41–56) 50 (43–56) 50 (43–54) 0.84
Sex <0.001
Male 72 (100) 347 (90.1) 85 (77.3)
Female 0 30 (7.8) 21 (19.1)
Transgender 0 8 (2.1) 4 (3.6)
Race 0.006
White 37 (51.4) 235 (61) 58 (52.7)
African American 23 (31.9) 86 (22.3) 43 (39.1)
Latino 6 (8.3) 37 (9.6) 8 (7.3)
Other 6 (8.3) 27 (7) 1 (0.9)
BMI, kg/m2 25.8 (26.5–28.8) 25.1 (22.4–29.6) 25.4 (23.1–28.4) 0.67
Systolic blood pressure, mm Hg 121 (113–134) 120 (111–131) 122 (111–132) 0.65
Diastolic blood pressure, mm Hg 78 (71–86) 76 (68–82) 73 (68–81) 0.16
Diabetes mellitus 3 (4.2) 23 (6) 7 (6.4) 0.81
Current smoker 24 (33.3) 112 (29.1) 61 (55.5) <0.001
History of smoking 40 (55.6) 207 (53.8) 86 (78.2) <0.001
CAD or CVA 0 25 (6.5) 8 (7.3) 0.08
Hypertension meds 12 (16.7) 98 (25.5) 30 (27.3) 0.22
Cholesterol meds 11 (15.3) 124 (32.2) 13 (11.8) <0.001
Statins 9 (12.5) 101 (26.2) 8 (7.3) <0.001
Alanine transaminase, IU/L 27 (21–36) 32 (23–43) 39 (26–61) 0.001
Aspartate transaminase, IU/L 28 (24–35) 31 (25–40) 41 (29–55) <0.001
All values shown are median (IQR) or N (%) number (percentage). BMI indicates body mass index; CAD indicates coronary artery disease; CVA, cerebrovascular accident; HCV, hepatitis C
virus infection; HIV, HIV infection; Meds, medications.
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levels remained highly significant in the multivariable
models.
PCSK9 Levels and Mortality
A total of 55 (9.7%) individuals died since the beginning of the
study: 33 HIV-monoinfected, 21 coinfected, and 1 control
subject followed for median of 3 years. Individuals who died
had 10% higher PCSK9 levels compared with those who lived
(95% CI 1% to 22%, P=0.066), which was reduced to 7% after
adjustment for HIV/HCV status (95% CI 4% to 18%, P=0.23).
Similar findings were present for PCSK9 levels and baseline
CAD/CVA (findings not shown).
Discussion
In this study, we demonstrate that HIV/HCV coinfection is
independently associated with high levels of PCSK9 compared
with HIV monoinfection and compared with uninfected
controls. We also describe a finding that we have termed
the apparent “PCSK9–lipid paradox,” which is also observed
when individuals are treated with statin therapy. That is,
despite the elevation in circulating PCSK9 levels that our
study demonstrates, lipids are lower in patients with HIV/HCV
coinfection. The mechanism of these findings may be related
at least in part to heightened inflammation, as evidenced by
inflammatory markers such as IL-6, which are nearly doubled
in the setting of HIV/HCV coinfection compared with
uninfected controls. This chronic inflammation may affect
the ability of the liver to synthesize lipoproteins and explain
the lower lipid levels we observed. The lipid paradox may also
be secondary to lower intracellular cholesterol, which can
drive a compensatory increase in PCSK9, similar to the
physiologic response observed with statin therapy. To our
knowledge, this is the first study to demonstrate a perturba-
tion of PCSK9 and LDL-C homeostasis in the setting of an
inflammatory state (HIV/HCV coinfection) that is physiolog-
ically similar to what occurs with statin therapy. Our findings
have important implications for the use of PCSK9 inhibitors in
HIV/HCV-coinfected patients as well as in those with other
inflammatory diseases, which may also be subject to such
alterations in PCSK9–LDL-C regulation. Finally, individuals
who died had higher PCSK9 levels than those who lived,
suggesting that PCSK9 inhibition may be beneficial in the
setting of HIV/HCV coinfection, a finding that will need to be
demonstrated in prospective randomized controlled studies.
Because of the high rates of dyslipidemia, cardiovascular
disease, and mortality associated with HIV and HCV coinfec-
tion, identifying therapies to lower risk in this unique patient
population is critical. Targeting dyslipidemia is one obvious
way to modulate this risk. The use of statins, which are
typically the first-line therapy in the general population to
treat dyslipidemia, may be somewhat limited among individ-
uals with HIV/HCV coinfection for many reasons. First,
preexisting liver fibrosis, cirrhosis, or abnormalities in liver
function tests may preclude the safe use of this therapy in
some patients.5 Second, significant drug–drug interactions of
particular statins with both HIV- and HCV-specific protease
inhibitors limit the type and dose of statin that can be used in
some patients with no other apparent contraindications.30–32
Most protease inhibitors inhibit the cytochrome P450 system,
resulting in elevated concentration–time curve for statins,33
which has resulted in death from rhabdomyolysis reported in
rare cases.34 For this reason, the use of lovastatin or
simvastatin in combination with protease inhibitor medication
is contraindicated and the maximum dose of atorvastatin is
reduced among individuals taking a protease inhibitor. Drug–
drug interactions have also been reported for statins such as
rosuvastatin, whose metabolism is independent of the
cytochrome P450 system.35 HIV/HCV-coinfected individuals
are at increased risk for cardiovascular disease, and among
coinfected individuals, hyperlipidemia is independently asso-
ciated with cardiovascular disease events,36 suggesting that
lipid lowering may reduce cardiovascular risk in this patient
population. While statin therapy may have an impact on HCV
replication, fibrosis, and hepatocellular carcinoma in the
setting of older HCV regimens,37 high-dose atorvastatin
therapy, which is commonly used among individuals with
Table 2. HIV Characteristics in Monoinfected and HCV-
Coinfected Individuals
HIV Infected
(n=385)
HIV/HCV
Coinfected
(n=110) P Value
HIV duration, y 15 (7–21) 15 (9–20) 0.87
HIV viral load,
copies/mL
75 (40–860) 75 (40–1450) 0.07
Current CD4 count,
cells/mm3
533 (357–739) 516 (303–701) 0.32
Nadir CD4 count,
cells/mm3
239 (100–399) 227 (93–365) 0.67
Off current ART 111 (28.8) 40 (45.5) <0.001
Opportunistic infection 199 (51.7) 63 (57.3) <0.001
Off ART, viral load
<75 copies
19 (4.9) 13 (11.8) 0.002
Off ART, viral load
>75 copies
92 (23.9) 37 (33.6)
On ART, viral load
>75 copies
41 (10.7) 14 (12.7)
On ART, viral load
<75 copies
233 (60.5) 46 (41.8)
All values expressed as median (IQR) or N (%): number (percentage). ART indicates
antiretroviral therapy; HCV, hepatitis C virus.
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acute coronary syndromes or coronary artery disease, has
been associated with severe hepatic injury in the setting of
chronic liver disease.38
Therefore, there is an unmet need to for identification of
novel agents that target dyslipidemia in this patient popula-
tion. Therapies involving PCSK9 inhibition are promising, but
the physiology of PCSK9 needs to be better understood in
HIV/HCV-coinfected individuals before their use in clinical
Figure 2. PCSK9 levels in uninfected controls, HIV-infected, and
HIV/HCV-coinfected individuals. The boxes represent IQR, the
outer bars represent the 1.5 IQR below 25th percentile and 1.5 IQR
above 75th percentile. The circles beyond the outer bars represent
extreme values. The marker inside the box indicates the mean
value. The line inside the box indicates the median value. Compared
with controls, HIV/HCV-coinfected individuals had 21% higher
PCSK9 levels while HIV-infected individuals had 9% higher PCSK9
levels (P=0.07). When compared with HIV-infected subjects, HIV/
HCV-coinfected individuals had 11% higher PCSK9 levels (P=0.008).
PCSK9 indicates proprotein convertase subtilisin kexin 9; HCV,
hepatitis C virus.
Figure 1. Lipid profiles in uninfected (black), HIV-infected (dark gray), and HIV/HCV-coinfected
(light gray) individuals. HDL-C indicates high-density lipoprotein cholesterol; LDL, low-density
lipoprotein cholesterol; HCV, hepatitis C virus. Bars on each column reflect the 95% CIs. HIV/HCV-
coinfected individuals had lower levels of total cholesterol, LDL-C, andHDL-C comparedwith bothHIV-
infected individuals and controls. Triglycerides were highest among individuals with HIV infection only
and lowest in controls.
Figure 3. IL-6 and PCSK9 are elevated in a stepwise and
parallel fashion in uninfected controls, HIV infection, and HIV/
HCV coinfection. IL-6 levels are shown in light gray; PCSK9 levels
are shown in dark grey. As shown, levels of IL-6 and PCSK9
increase in stepwise from uninfected individuals, HIV-infected,
and HIV/HCV-coinfected individuals. PCSK9 indicates proprotein
convertase subtilisin kexin 9; HCV, hepatitis C virus; IL,
interleukin.
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trials, because PCSK9–LDL-C homeostasis may be altered in
the setting of inflammation.
PCSK9–Lipid Paradox in HIV/HCV Coinfection
No correlation between LDL-C and PCSK9 has been previously
described in the context of HCV infection, except in a small
study of individuals with HCV genotypes 1 and 3.39 In our
study, we are able to validate the findings of this small study
and further demonstrate that HIV/HCV-associated inflamma-
tion (as mediated by IL-6) is most likely responsible for this
apparent paradox. We also show that hepatic injury and
necrosis, with “release” of PCSK9 from hepatocytes into the
bloodstream (akin to the release of transaminases during liver
injury), are unlikely to explain our findings.
IL-6 as a Mediator of the Apparent PCSK9–Lipid
Paradox
In the setting of a chronic inflammatory disease of the liver,
such as HCV, systemic inflammatory cytokines, such as IL-6,
are released from multiple inflammatory cell types, including
monocytes. Although the exact mechanism of regulation has
not been characterized, PCSK9 and IL-6 are known to be
closely interrelated. In healthy individuals with a PCSK9 loss
of function allele, less IL-6 is produced in response to
lipopolysaccharide-induced inflammation.40 In our study, we
report that PCSK9 and IL-6 are modestly correlated and
increase in a parallel, stepwise fashion with increasing
inflammation. In aggregate, these findings suggest that IL-6
may be associated with increased PCSK9 expression and/or
secretion.
Lower Lipids in HIV/HCV Coinfection Despite a
Higher PCSK9
More of the HIV-monoinfected individuals were taking statin
therapy compared with controls, which is the likely reason
why their LDL-C levels were lower. The unexpected finding of
lower LDL-C in HIV/HCV-coinfected patients has several
possible underlying mechanisms. One possible explanation is
that the increased liver fibrosis that exists in HIV/HCV
coinfection5 results in reduced function of the liver and
decreased production of lipoproteins. Prior studies from our
group have already demonstrated that levels of atherogenic
lipids, such as LDL-C, are impaired in the setting of HIV/HCV
coinfection.10 In this study, we also demonstrate that TC,
LDL-C, and HDL-C levels were all lower in HIV/HCV-
coinfected subjects compared with controls, consistent with
this hypothesis and confirming our previous findings.
The lower lipid levels that we observed may also be
because of suppression of lipoprotein production from the
liver in the setting of chronic inflammation. In other clinical
settings, serum lipids are an inverse acute phase reactant and
thus are decreased during states of inflammation.41,42 Higher
IL-6 levels were associated with decreased serum lipids in the
setting of HIV infection.12 HIV and HCV infections are both
chronic inflammatory diseases that may result in decreased
lipid production. The elevation in PCSK9 may reflect “uncou-
pling” of this regulatory mechanism or, more likely, a
compensatory increase in PSCK9 in response to less intra-
cellular cholesterol. Given the modest negative association of
IL-6 with LDL-C and our findings correlating IL-6 and PCSK9
levels, IL-6 may play a key role in the lipid paradox observed in
our study. Finally, as oxidized LDL levels are elevated in the
setting of HIV43 another mechanism underling the low LDL
levels we observed may be accelerated removal of oxidatively
modified LDL.
Roles of IL-6 and hsCRP
Both IL-6 and hsCRP are inflammatory markers independently
associated with cardiovascular risk in HIV infection.44 IL-6 is
higher in HIV/HCV coinfection compared with HIV monoin-
fection and is an inflammatory marker independently associ-
ated with cardiovascular risk in both HIV45 and HCV
infection.46 IL-6 has also been thought to play a role in
HCV- and HIV-associated liver fibrosis and inflammation.47
Even among treated and suppressed HIV-infected individuals,
elevated IL-6 is independently predictive of adverse cardio-
vascular outcomes45 as well as overall mortality.48
Our findings suggest that heightened inflammation, as
mediated by IL-6, may indeed represent the biochemical link
between HIV/HCV coinfection and elevated PCSK9 levels as
well as decreased LDL-C levels. This relationship may be
bidirectional (PCSK9 regulating levels of IL-6) because healthy
individuals with PCSK9 loss of function mutations have less
IL-6 in response to lipopolysaccharide-induced inflamma-
tion.40 While randomized clinical trials of PCSK9 inhibition in
this unique patient population will be required for ultimate
proof-of-concept, it is biologically plausible that PCSK9 and IL-
6 are coregulated and inhibition of PCSK9 in HIV infection
may lead to decreased levels of IL-6, which may have an
impact on cardiovascular risk and mortality in HIV infection.
Conversely, inhibition of IL-6 might reduce PCSK9 levels and
thus potentially affect lipoprotein metabolism.
In contrast, we were unable to demonstrate a significant
association between hsCRP and PCSK9 levels in HIV-infected
individuals or among HIV/HCV-coinfected individuals. Previ-
ous studies have reported that hsCRP does not correlate well
with degree of HIV control, as assessed based on viral load or
CD4 count.49 Further, in HIV/HCV-coinfected patients, hsCRP
levels tend to be lower because of impaired synthetic function
of the liver11 and, therefore, are not good markers of systemic
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inflammation in this particular clinical setting. Our results
suggest that PCSK9 and hsCRP are not likely to be linked.
This is not a surprising finding as previous clinical trials of
PCSK9 inhibition among individuals without HIV infection have
not shown a significant impact on hsCRP,50 suggesting that
the regulation of these 2 proteins is likely mechanistically
unrelated.
Limitations
Our analysis is subject to the usual limitations of any
observational analysis: although we have rigorously adjusted
our model for multiple factors, including demographic factors,
statin use, and smoking, there is always the possibility that
residual confounding remains. In addition, although PCSK9
has a dose-dependent relationship with statin use, we were
not able to adjust for the dose and potency of statin used. We
did not have HCV viral load or genotype available for the
majority of our coinfected patients and were not able to
adjust for degree of HCV viral activity. Finally, because this
was an observational study, we are only able to report
associations, and not causation, from our findings.
Clinical Perspective
PCSK9 inhibitors have been used to lower LDL-C in a number
of patient populations, including statin-intolerant patients and
those with familial hypercholesterolemia, and have a safety
profile that is extremely favorable along with no known drug–
drug interactions. However, their role in unique populations,
such as those with chronic inflammatory diseases, remains
uncertain. HIV/HCV coinfection provides a unique clinical
scenario that may mimic what occurs during statin therapy,
where PCSK9 is increased while LDL-C is decreased. This
may, in part, be mediated by IL-6, which may have important
implications for anti-PCSK9 therapies in other inflammatory
diseases in which IL-6 is upregulated (ie, rheumatoid arthritis).
Translational implications
Additional clinical studies are warranted to confirm our
findings and to test if PCSK9 inhibition will be safely tolerated,
lower lipid levels, and potentially reduce IL-6 levels among
individuals with HIV and HCV coinfection.
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SUPPLEMENTAL MATERIAL 
 
Figure S1. Correlation plot showing correlation of PCSK9 with Interleukin-6 (IL-6) (a) and 
LDL-C (b) in all patients from the study cohort. 
 
Figure S1a. Positive correlation of PCSK9 and IL-6 among all study subjects 
  
Figure S1b: Negative Correlation between IL-6 and LDL in Study Subjects  
 
 
 
  
